Wassim Kassouf
- Professor of Urology
- Stephen Jarislowsky Chair in Urology
MD, CM, FRCSC
American Urological Association Young Urologist of the Year
Quebec FRQS Distinguished Research Scholar Award
Bladder Cancer Canada Medical Leadership Award
Everett C. Reid Teaching Excellence Award.
Clinical practice focuses on all aspects of urologic oncology (including bladder, prostate, renal, testes, and penile cance
Oncology (including bladder, prostate, renal, testes, and penile cancer
Dr Wassim Kassouf completed a fellowship in urologic oncology at M. D. Anderson Cancer Center in Houston, Texas following medical school and urology residency at 黑料不打烊 University. Dr. Kassouf鈥檚 clinical practice focuses on all aspects of urologic oncology (including bladder, prostate, renal, testes, and penile cancer) whereas his clinical and translational research program focuses on refining organ preservation approaches in bladder cancer. He is a tenured Professor in the Division of Urology and past Vice-Chair of academic affairs, for the Department of Surgery at 黑料不打烊 University. He has also served as urology program director for 6 years and as member of the Royal College Examination board committee.
He has led several national guidelines for optimizing quality of care in urologic cancer management and has published over 395 peer-review manuscripts and book chapters. His research supported by independent peer-reviewed grant funding from the US Dept of Defense, Canadian Institutes of Health Research, and Cancer Research Society. He is bladder cancer section editor for CUAJ and has served as associate editor for BMC Urology, and is/has been on the editorial board of Urology, Clinical Cancer Investigation Journal, and International Brazilian Journal of Urology. He is a cofounder of Bladder Cancer Canada, GU co-chair of the Canadian Clinical Trials Group, and an executive member of the NIH Genitourinary steering committee. Dr Kassouf is a graduate of the AUA Leadership Program and received several prestigious awards including the American Urological Association Young Urologist of the Year, AUA Research Scholar Award, Quebec FRQS Distinguished Research Scholar Award, Bladder Cancer Canada Medical Leadership Award, and the Everett C. Reid Teaching Excellence Award.
听
1.Marcq G, Cury F, Brimo F, Kassouf W. Impact of Programmed Death-ligand 1 Expression on Outcomes in Patients with bladder cancer Treated with radiation. Eur Urol Open Sci. 2022
2.Shinde-Jadhav S, Mansure JJ, Rayes RF, Marcq G, Ayoub M, Skowronski R, Kool R, Bourdeau F, Brimo F, Spicer J, Kassouf W. Role of neutrophil extracellular traps in radiation resistance of invasive bladder cancer. Nat Commun. 2021 May 13;12(1):2776. doi: 10.1038/s41467-021-23086-z.PMID: 33986291
3.Tholomier C, Marcq G, Shinde-Shadhav S, Ayoub M, Huang JM, Kool R, Skowronski R, Brimo F, Mansure JJ, and Kassouf W. Optimizing sequence of PD-L1 immune-checkpoint inhibitors and radiation therapy in bladder cancer. Bladder Cancer 6:295-302, 2020.
4.Marcq G, Souhami L, Cury FL, Salimi A, Aprikian A, Tanguay S, Vanhuyse M, Rajan R, Brimo F, Mansure JJ, Kassouf W. Phase I Trial of Atezolizumab plus Trimodal Therapy in Patients with localized Muscle-Invasive Bladder Cancer. Int J Radiat Oncol Biol Phys. 2021 Jan 6:S0360-3016(20)34729-5. doi: 10.1016/j.ijrobp.2020.12.033
5.Rompr茅-Brodeur A. Ayoub M, Shinde-Jadhav S, Piccirillo C, Seuntjens J, Fadi Brimo F, Mansure J, Kassouf W. PD-1/PD-L1 Immune-Checkpoint Inhibition with Radiation in Bladder Cancer: In Situ and Abscopal Effects. Mol Cancer Ther, 2020 19(1):211-22, doi: 10.1158/1535-7163.MCT-18-0986
6.Ayoub M, Shinde-Jadhav S, Mansure JJ, Alvarez F, Connell T, Seuntjens J, Piccirillo CA, Kassouf W. The immune mediated role of extracellular HMGB1 in a heterotopic model of bladder cancer radioresistance. Sci Rep. 2019 Apr 23;9(1):6348. doi: 10.1038/s41598-019-42864-w.
7.Yu A, Mansure JJ, Solanki S, Siemens DR, Koti M, Dias ABT, Burnier MM, Brimo F, Kassouf W. Presence of lymphocytic infiltrate cytotoxic T lymphocyte CD3+, CD8+, and immunoscore as prognostic marker in patients after radical cystectomy. PLoS One. 2018 Oct 11;13(10):e0205746. doi: 10.1371/journal.pone.0205746. eCollection 2018.
8.Bachir B, Souhami L, Mansure JJ, Brimo F, Vanhuyse M, Sturgeon J, Cury F, Aprikian A, Tanguay S, and Kassouf W. Phase I clinical trial of everolimus combined with trimodality therapy in patients with muscle invasive bladder cancer. Bladder Cancer. 2017, 27:105-12.
9. Shrivastava S, Mansure JJ, Almajed W, Cury F, Ferbeyre G, Popovic M, Seuntjens J, Kassouf W. Role of HMGB1 in radio-resistance of bladder cancer. Mol Cancer Ther, 15(3):471-9, 2016.
10. Kamat AM, Hahn N, Efstathiou J, Lerner S, Malmstrom P, Choi W, Guo C, and Kassouf W. Bladder cancer. Lancet, 2016 Dec 3;388(10061):2796-2810
听
